Trial Profile

The UK Collaborative HIV Cohort Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Antiretrovirals; Atazanavir; Lopinavir
Indications HIV infections
Focus Therapeutic Use
Acronyms UK CHIC

Most Recent Events

16 Feb 2022 Results from this and other study compared virological suppression and all-cause mortality between different InSTI- and non-InSTI-based regimens among PWH starting ART in Europe and North America, presented at the 29th Conference on Retroviruses and Opportunistic Infections
20 Feb 2017 Results of subgroup analysis assessing kidney function in patients who switched from atazanavir or lopinavir to darunavir published in the AIDS.
24 Jan 2017 Results (n=15983) assessing risk factors of developing severe renal tubulopathy in patients treated with tenofovir disoproxil fumarate, published in the Journal of Infection

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com